Epratuzumab

• CAT Number: I042424
• CAS Number: 205923-57-5
• Purity: ≥95%

Epratuzumab (Cat No.: I042424) is a humanized monoclonal antibody that targets CD22, a cell surface glycoprotein expressed on mature B cells. By binding to CD22, epratuzumab modulates B cell signaling and reduces their activity without causing extensive depletion, making it a promising therapeutic for autoimmune diseases like systemic lupus erythematosus (SLE). It has also been investigated for treating B cell malignancies such as non-Hodgkin lymphoma. Epratuzumab offers a targeted approach to immunomodulation with the potential for fewer side effects than broad immunosuppressants.

Reference

[1]. Carnahan J, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3982S-90S.
[Content Brief]